{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:06:51Z","timestamp":1786118811415,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,5]]},"DOI":"10.1097\/wnf.0b013e31803354f6","type":"journal-article","created":{"date-parts":[[2007,5,29]],"date-time":"2007-05-29T04:01:30Z","timestamp":1180411290000},"page":"127-135","source":"Crossref","is-referenced-by-count":24,"title":["Combination of Olanzapine With Opioid-Agonists in the Treatment of Heroin-Addicted Patients Affected by Comorbid Schizophrenia Spectrum Disorders"],"prefix":"10.1097","volume":"30","author":[{"given":"Gilberto","family":"Gerra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilberto","family":"Di Petta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"D'Amore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Iannotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bardicchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Falorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Coacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Strepparola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Campione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfio","family":"Lucchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Vedda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Serio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezio","family":"Manzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maina","family":"Antonioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Bertacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Moi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Zaimovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"2","key":"R1-1-20210203","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/105504999305929","article-title":"Pergolide mesylate for cocaine abuse: a controlled preliminary trial.","volume":"8","author":"Levin","year":"1999","journal-title":"Am J Addict"},{"issue":"5","key":"R2-1-20210203","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/alcalc\/36.5.419","article-title":"Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.","volume":"36","author":"Rubio","year":"2001","journal-title":"Alcohol Alcohol"},{"issue":"5","key":"R3-1-20210203","first-page":"321","article-title":"Fluoxetine (FX) efficacy in the treatment of cocaine dependence methadone maintenance patients. Interaction with plasma levels.","volume":"27","author":"Bano","year":"1999","journal-title":"Actas Esp Psiquiatr"},{"issue":"2","key":"R4-1-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1300\/J069v21n02_01","article-title":"Bupropion treatment for cocaine abuse and adult attention-deficit\/hyperactivity disorder.","volume":"21","author":"Levin","year":"2002","journal-title":"J Addict Dis"},{"issue":"3","key":"R6-1-20210203","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0376-8716(98)00032-5","article-title":"Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts.","volume":"50","author":"Petrakis","year":"1998","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"R7-1-20210203","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0376-8716(00)00208-8","article-title":"Fluoxetine treatment of cocaine-dependent patients with major depressive disorder.","volume":"63","author":"Schmitz","year":"2001","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"R8-1-20210203","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/10673229909017206","article-title":"Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?","volume":"6","author":"Green","year":"1999","journal-title":"Harv Rev Psychiatry"},{"issue":"12","key":"R9-1-20210203","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1176\/ajp.154.12.1760","article-title":"Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine.","volume":"154","author":"Fava","year":"1997","journal-title":"Am J Psychiatry"},{"issue":"6","key":"R10-1-20210203","first-page":"452","article-title":"Potential benefits of quetiapine in the treatment of substance dependence disorders.","volume":"29","author":"Sattar","year":"2004","journal-title":"J Psychiatry Neurosci"},{"issue":"2","key":"R11-1-20210203","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0014-2999(00)00935-3","article-title":"Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum.","volume":"412","author":"Westerink","year":"2001","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"R14-1-20210203","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1521\/pedi.1997.11.3.279","article-title":"Interrater reliability and internal consistency of the structured clinical interview for DSM-IV axis II personality disorders (SCID-II), version 2.0.","volume":"11","author":"Maffei","year":"1997","journal-title":"J Personal Disord"},{"issue":"1","key":"R16-1-20210203","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2003.11.017","article-title":"Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome.","volume":"75","author":"Gerra","year":"2004","journal-title":"Drug Alcohol Depend"},{"key":"R17-1-20210203","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pnpbp.2005.10.007","article-title":"Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study.","volume":"30","author":"Gerra","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"R18-1-20210203","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/BF02246063","article-title":"Haloperidol increases smoking in patients with schizophrenia.","volume":"119","author":"McEvoy","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"R19-1-20210203","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/oxfordjournals.schbul.a033464","article-title":"The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia.","volume":"26","author":"Drake","year":"2000","journal-title":"Schizophr Bull"},{"issue":"suppl 3","key":"R20-1-20210203","first-page":"3","article-title":"Antipsychotics standard of care redefining the definition of atypical antipsychotics.","volume":"61","author":"Casey","year":"2000","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"R21-1-20210203","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1176\/ajp.156.7.1119a","article-title":"Clozapine for substance-abusing schizophrenic patients.","volume":"156","author":"Tsuang","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"4","key":"R22-1-20210203","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0740-5472(01)00205-7","article-title":"Olanzapine treatment for patients with schizophrenia and substance abuse.","volume":"21","author":"Littrell","year":"2001","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"R23-1-20210203","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0376-8716(03)00009-7","article-title":"A pilot trial of olanzapine for the treatment of cocaine dependence.","volume":"70","author":"Kampman","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"suppl 1","key":"R24-1-20210203","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/j.1360-0443.2005.00990.x","article-title":"A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10\/L-carnitine for the treatment of cocaine dependence.","volume":"100","author":"Reid","year":"2005","journal-title":"Addiction"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002826-200705000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:38:57Z","timestamp":1786034337000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002826-200705000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31803354f6","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2007,5]]}}}